Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume 6, Issue 1, Pages 41-47Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ECP.12.74
Keywords
drug repurposing; drug-target network; multitargeting design; off-target; polypharmacology; side effects
Categories
Funding
- University Cancer Foundation via the Institutional Research Grant program
- NCI SPORE [P50CA140388, 5P50CA127001]
- NIH [5R01CA138702-03]
- NATIONAL CANCER INSTITUTE [R01CA138702, P50CA127001, P50CA140388] Funding Source: NIH RePORTER
Ask authors/readers for more resources
In recent years, even with remarkable scientific advancements and a significant increase of global research and development spending, drugs are frequently withdrawn from markets. This is primarily due to their side effects or toxicities. Drug molecules often interact with multiple targets, coined as polypharmacology, and the unintended drug-target interactions could cause side effects. Polypharmacology remains one of the major challenges in drug development, and it opens novel avenues to rationally design the next generation of more effective, but less toxic, therapeutic agents. This review outlines the latest progress and challenges in polypharmacology studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
